CBIO vs. OPK, GERN, RGLS, ZBIO, MYGN, RIGL, EBS, VSTM, XOMA, and VNDA
Should you be buying Catalyst Biosciences stock or one of its competitors? The main competitors of Catalyst Biosciences include OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Zenas Biopharma (ZBIO), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), Verastem (VSTM), XOMA (XOMA), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry.
Catalyst Biosciences vs. Its Competitors
Catalyst Biosciences (NASDAQ:CBIO) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, community ranking, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.
Catalyst Biosciences has a net margin of 0.00% compared to OPKO Health's net margin of -18.65%. OPKO Health's return on equity of -9.76% beat Catalyst Biosciences' return on equity.
Catalyst Biosciences has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
6.0% of Catalyst Biosciences shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 2.9% of Catalyst Biosciences shares are owned by company insiders. Comparatively, 49.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
OPKO Health received 205 more outperform votes than Catalyst Biosciences when rated by MarketBeat users. However, 68.29% of users gave Catalyst Biosciences an outperform vote while only 65.60% of users gave OPKO Health an outperform vote.
Catalyst Biosciences has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Catalyst Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Catalyst Biosciences had 5 more articles in the media than OPKO Health. MarketBeat recorded 8 mentions for Catalyst Biosciences and 3 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.58 beat Catalyst Biosciences' score of 0.00 indicating that OPKO Health is being referred to more favorably in the news media.
OPKO Health has a consensus target price of $2.75, suggesting a potential upside of 106.77%. Given OPKO Health's stronger consensus rating and higher probable upside, analysts plainly believe OPKO Health is more favorable than Catalyst Biosciences.
Summary
OPKO Health beats Catalyst Biosciences on 13 of the 18 factors compared between the two stocks.
Get Catalyst Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalyst Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CBIO) was last updated on 6/17/2025 by MarketBeat.com Staff
Buy CBIO Stock Free CBIO Stock Alerts